Discover investment opportunities in Psychedelic Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Psychedelic Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Psychedelic Stocks using our Smart AI Filter.
8 stocks found for "Psychedelic Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.28 Risk measure | ±88.5% Price volatility | -5.2 Valuation | 0.00% Annual yield | |||
0.61 Risk measure | ±21.0% Price volatility | 18.1 Valuation | 5.03% Annual yield | |||
1.02 Risk measure | ±100.0% Price volatility | -0.3 Valuation | 0.00% Annual yield | |||
0.12 Risk measure | ±100.0% Price volatility | — Valuation | 0.00% Annual yield | |||
0.49 Risk measure | ±66.7% Price volatility | -1.1 Valuation | 0.00% Annual yield | |||
0.82 Risk measure | ±100.0% Price volatility | -13.0 Valuation | 0.00% Annual yield | |||
1.18 Risk measure | ±85.7% Price volatility | -17.1 Valuation | 0.00% Annual yield | |||
1.17 Risk measure | ±100.0% Price volatility | -4.1 Valuation | 0.00% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
The average of price targets set by Wall Street analysts indicates a potential upside of 107.3% in GH Research (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read moreThe mean of analysts' price targets for Mind Medicine MindMed (MNMD) points to a 237.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read moreMedia company Global Trac Solutions, Inc. (OTCP:PSYC) and authorities behind psychedelic news and information platform Psychedelic Spotlight, announced that Psychedelic Spotlight will host its first 'CEO Roundtable' on Feb. 15. The event is scheduled to be streamed live on YouTube via The Psychedelic Investor channel, and will be moderated by James Hallifax, journalist and content director for Psychedelic Spotlight.
Read moreQ: How have psychedelic stocks like MNMD and CMPS performed historically in volatile markets?
A: Psychedelic stocks, including MNMD and CMPS, often exhibit high volatility due to their emerging industry status and regulatory uncertainties. Historically, these stocks have seen significant fluctuations influenced by clinical trial news and legislative changes.
Q: Are companies like ATAI involved in psychedelic research offering dividends?
A: ATAI, similar to other psychedelic research companies, primarily focuses on growth and reinvestment. Most do not offer dividends as they allocate resources toward R&D and expanding their therapeutic pipelines.
Q: What sectors are impacted by the growth of psychedelic stocks like RLMD and CYBN?
A: Psychedelic stocks like RLMD and CYBN primarily impact the healthcare and biotechnology sectors. Their potential breakthrough treatments for mental health conditions influence market dynamics and investor interest in these fields.
Q: Do psychedelic stocks like GHRS and CYBN show any potential for ESG investment?
A: While psychedelic stocks like GHRS and CYBN may not traditionally focus on ESG factors, they pursue innovations in mental health treatment, aligning with social impact goals. Investors consider their therapeutic potential as a positive societal contribution.
Q: How does geographic location affect the psychedelic stocks like MYCOF?
A: MYCOF, a Canadian company, benefits from Canada's progressive stance on psychedelic research, providing a supportive regulatory environment. Geographic location affects their access to financing, research opportunities, and market expansion.
Q: What are the risks associated with investing in early-stage psychedelic companies like ENOB?
A: ENOB, as an early-stage psychedelic company, faces risks including regulatory hurdles, high research and development costs, potential clinical trial failures, and market competition influencing stock performance.